These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28323678)

  • 21. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
    Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results.
    Lafuente M; Ortín L; Argente M; Guindo JL; López-Bernal MD; López-Román FJ; García MJ; Domingo JC; Lajara J
    Retina; 2017 Jul; 37(7):1277-1286. PubMed ID: 27787443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.
    Patrao NV; Antao S; Egan C; Omar A; Hamilton R; Hykin PG; Sivaprasad S; Rajendram R;
    Am J Ophthalmol; 2016 Dec; 172():51-57. PubMed ID: 27637784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.
    Chatziralli I; Santarelli M; Patrao N; Nicholson L; Zola M; Rajendram R; Hykin P; Sivaprasad S
    Eye (Lond); 2017 Nov; 31(11):1594-1599. PubMed ID: 28622321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
    Li X; Dai H; Li X; Han M; Li J; Suhner A; Lin R; Wolf S;
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):529-541. PubMed ID: 30645696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
    Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
    Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
    [No Abstract]   [Full Text] [Related]  

  • 30. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.
    Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU
    Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
    Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
    Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
    Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Mar; 17(1):28. PubMed ID: 28292270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema.
    Chatziralli I; Chatzipantelis A; Dimitriou E; Mpourouki E; Theodossiadis G; Theodossiadis P
    Clin Exp Optom; 2018 May; 101(3):397-399. PubMed ID: 29134696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
    Seo KH; Yu SY; Kim M; Kwak HW
    Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.
    Murakami T; Suzuma K; Uji A; Yoshitake S; Dodo Y; Fujimoto M; Yoshitake T; Miwa Y; Yoshimura N
    Jpn J Ophthalmol; 2018 May; 62(3):292-301. PubMed ID: 29460019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
    Stefanickova J; Cunha-Vaz J; Ulbig M; Pearce I; Fernández-Vega Sanz A; Theodossiadis P; Kodjikian L; Izmailov A; Muston D; Vassilev Z; Lamotte B; Tückmantel C; Friedl S; Altemark A; Schwarz HJ; Katz T;
    Acta Ophthalmol; 2018 Dec; 96(8):e942-e949. PubMed ID: 29696809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.